Top

Published in:

Open Access 01-01-2020 | Original Article

Gene Expression Profiles in Chemokine (C-C Motif) Ligand 21-Overexpressing Pancreatic Cancer Cells

Authors: Kai Cui, Hongsheng Zou, Mingliang Shi, Yang Ou, Lu Han, Bo Zhang, Dawei Hu, Sheng Li

Published in: Pathology & Oncology Research | Issue 1/2020

Abstract

Chemokine (C-C Motif) ligand 21 (CCL21) plays an important role in tumor immunity. However, the molecular mechanisms by which CCL21 regulates tumor immunity remain largely unknown. In this study, we successfully generated a lentiviral vector expressing human CCL21 (Lenti-hCCL21), which was confirmed by biological assays. The Lenti-hCCL21 was transduced into PANC-1 cells, a chemokine (C-C motif) receptor 7 (CCR7)-positive human pancreatic cancer cell line. We used the scratch wound and transwell assays to measure cell migration of the CCL21-overexpressing PANC-1 cells. A DNA microarray assay was performed to determine gene expression profiles. The results showed that CCL21 lentiviral transduction significantly up- or down-regulated a panel of tumor-associated genes, although CCL21 appeared to have no effect on PANC-1 cell migration. Importantly, CCL21 promoted matrix metallopeptidase-9 (MMP-9) expression in PANC-1 cells. CCL21 regulates pancreatic cancer immunity possibly through governing the expression of a panel of tumor-associated genes, including MMP-9.

Yadav D, Lowenfels AB (2013) The epidemiology of pancreatitis and pancreatic cancer. Gastroenterology 144(6):1252–1261. https://doi.org/10.1053/j.gastro.2013.01.068 CrossRefPubMedPubMedCentral

Sozzani S, Locati M, Allavena P, Van Damme J, Mantovani A (1996) Chemokines: a superfamily of chemotactic cytokines. Int J Clin Lab Res 26(2):69–82CrossRef

Griffith JW, Sokol CL, Luster AD (2014) Chemokines and chemokine receptors: positioning cells for host defense and immunity. Annu Rev Immunol 32:659–702. https://doi.org/10.1146/annurev-immunol-032713-120145 CrossRefPubMed

Gunn MD, Tangemann K, Tam C, Cyster JG, Rosen SD, Williams LT (1998) A chemokine expressed in lymphoid high endothelial venules promotes the adhesion and chemotaxis of naive T lymphocytes. Proc Natl Acad Sci U S A 95(1):258–263CrossRef

Warnock RA, Campbell JJ, Dorf ME, Matsuzawa A, McEvoy LM, Butcher EC (2000) The role of chemokines in the microenvironmental control of T versus B cell arrest in Peyer's patch high endothelial venules. J Exp Med 191(1):77–88CrossRef

Willimann K, Legler DF, Loetscher M, Roos RS, Delgado MB, Clark-Lewis I, Baggiolini M, Moser B (1998) The chemokine SLC is expressed in T cell areas of lymph nodes and mucosal lymphoid tissues and attracts activated T cells via CCR7. Eur J Immunol 28(6):2025–2034. https://doi.org/10.1002/(SICI)1521-4141(199806)28:06<2025::AID-IMMU2025>3.0.CO;2-C CrossRefPubMed

Kirk CJ, Hartigan-O'Connor D, Mule JJ (2001) The dynamics of the T-cell antitumor response: chemokine-secreting dendritic cells can prime tumor-reactive T cells extranodally. Cancer Res 61(24):8794–8802PubMed

Ahn GO, Brown JM (2008) Matrix metalloproteinase-9 is required for tumor vasculogenesis but not for angiogenesis: role of bone marrow-derived myelomonocytic cells. Cancer Cell 13(3):193–205. https://doi.org/10.1016/j.ccr.2007.11.032 CrossRefPubMedPubMedCentral

Nagakawa Y, Aoki T, Kasuya K, Tsuchida A, Koyanagi Y (2002) Histologic features of venous invasion, expression of vascular endothelial growth factor and matrix metalloproteinase-2 and matrix metalloproteinase-9, and the relation with liver metastasis in pancreatic cancer. Pancreas 24(2):169–178CrossRef

10.

Wang J, Zhang X, Thomas SM, Grandis JR, Wells A, Chen ZG, Ferris RL (2005) Chemokine receptor 7 activates phosphoinositide-3 kinase-mediated invasive and prosurvival pathways in head and neck cancer cells independent of EGFR. Oncogene 24(38):5897–5904. https://doi.org/10.1038/sj.onc.1208740 CrossRefPubMed

11.

Sanchez-Sanchez N, Riol-Blanco L, de la Rosa G, Puig-Kroger A, Garcia-Bordas J, Martin D, Longo N, Cuadrado A, Cabanas C, Corbi AL, Sanchez-Mateos P, Rodriguez-Fernandez JL (2004) Chemokine receptor CCR7 induces intracellular signaling that inhibits apoptosis of mature dendritic cells. Blood 104(3):619–625. https://doi.org/10.1182/blood-2003-11-3943 CrossRefPubMed

12.

Sancho M, Vieira JM, Casalou C, Mesquita M, Pereira T, Cavaco BM, Dias S, Leite V (2006) Expression and function of the chemokine receptor CCR7 in thyroid carcinomas. J Endocrinol 191(1):229–238. https://doi.org/10.1677/joe.1.06688 CrossRefPubMed

13.

Sperveslage J, Frank S, Heneweer C, Egberts J, Schniewind B, Buchholz M, Bergmann F, Giese N, Munding J, Hahn SA, Kalthoff H, Kloppel G, Sipos B (2012) Lack of CCR7 expression is rate limiting for lymphatic spread of pancreatic ductal adenocarcinoma. Int J Cancer 131(4):E371–E381. https://doi.org/10.1002/ijc.26502 CrossRefPubMed

14.

Roy I, Zimmerman NP, Mackinnon AC, Tsai S, Evans DB, Dwinell MB (2014) CXCL12 chemokine expression suppresses human pancreatic cancer growth and metastasis. PLoS One 9(3):e90400. https://doi.org/10.1371/journal.pone.0090400 CrossRefPubMedPubMedCentral

15.

Zhao B, Cui K, Wang CL, Wang AL, Zhang B, Zhou WY, Zhao WH, Li S (2011) The chemotactic interaction between CCL21 and its receptor, CCR7, facilitates the progression of pancreatic cancer via induction of angiogenesis and lymphangiogenesis. J Hepatobiliary Pancreat Sci 18(6):821–828. https://doi.org/10.1007/s00534-011-0395-4 CrossRefPubMed

16.

Lin Y, Sharma S, John MS (2014) CCL21 cancer immunotherapy. Cancers (Basel) 6(2):1098–1110. https://doi.org/10.3390/cancers6021098 CrossRef

17.

Turnquist HR, Lin X, Ashour AE, Hollingsworth MA, Singh RK, Talmadge JE, Solheim JC (2007) CCL21 induces extensive intratumoral immune cell infiltration and specific anti-tumor cellular immunity. Int J Oncol 30(3):631–639PubMed

18.

Zhang L, Wang D, Li Y, Liu Y, Xie X, Wu Y, Zhou Y, Ren J, Zhang J, Zhu H, Su Z (2016) CCL21/CCR7 Axis contributed to CD133+ pancreatic cancer stem-like cell metastasis via EMT and Erk/NF-kappaB pathway. PLoS One 11(8):e0158529. https://doi.org/10.1371/journal.pone.0158529 CrossRefPubMedPubMedCentral

19.

Xu Y, Li Z, Jiang P, Wu G, Chen K, Zhang X, Li X (2015) The co-expression of MMP-9 and Tenascin-C is significantly associated with the progression and prognosis of pancreatic cancer. Diagn Pathol 10:211. https://doi.org/10.1186/s13000-015-0445-3 CrossRefPubMedPubMedCentral

Title: Gene Expression Profiles in Chemokine (C-C Motif) Ligand 21-Overexpressing Pancreatic Cancer Cells
Authors: Kai Cui
Hongsheng Zou
Mingliang Shi
Yang Ou
Lu Han
Bo Zhang
Dawei Hu
Sheng Li
Publication date: 01-01-2020
Publisher: Springer Netherlands
Published in: Pathology & Oncology Research / Issue 1/2020
Print ISSN: 1219-4956
Electronic ISSN: 1532-2807
DOI: https://doi.org/10.1007/s12253-018-0390-z

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2020

PPM1D Functions as Oncogene and is Associated with Poor Prognosis in Esophageal Squamous Cell Carcinoma

Different Prognostic Implications of Aquaporin-1 and Aquaporin-5 Expression among Different Histological Types of Ovarian Carcinoma

High Expression of PhospholipaseD2 Induced by Hypoxia Promotes Proliferation of Colon Cancer Cells through Activating NF- κ Bp65 Signaling Pathway

A Novel Genes Signature Associated with the Progression of Polycystic Ovary Syndrome

Precursor Lesions of the Vocal Cord: a Study on the Diagnostic Role of Histomorphology, Histometry and Ki-67 Proliferation

Immunomodulatory Effect of Lentinan on Aberrant T Subsets and Cytokines Profile in Non-small Cell Lung Cancer Patients

Keynote webinar | Spotlight on antibody–drug conjugates in cancer